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May Supplement 20094S Plenary SessionsConclusion: Parenchymal loss occurs in 31% of patients and is associ-
ated with markers of impaired parenchymal perfusion (RI and GSG) at the
time of intervention. Pre-existing renal size or volumes were not predictive
of parenchymal loss. Parenchymal loss is associated with a significant de-
crease in survival and a marked increased renal related morbidity and
progression to hemodialysis. Monitoring parenchymal loss will identify
high-risk patients after renal intervention.
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SS9.
Successful Management of Acute Complicated Type B Dissections with
TEVAR and Adjunctive Endovascular Techniques: Malperfusion Ver-
sus Rupture
Elena Y. Rakhlin, Wilson Y. Szeto, Ronald M. Fairman, Benjamin M.
Jackson, G. William Moser, Edward Y. Woo. Hospital of University of
Pennsylvania, Philadelphia, PA
Objective: Complicated acute type B aortic dissections require urgent
intervention. Our group has previously reported successful treatment of this
condition with TEVAR. We report our continued experience, and contrast
the technical aspects and outcomes of malperfusion vs. rupture.
Methods: From 2004-2008, 43 patients (60 13 years; 28 men) with
an acute complicated type B dissection underwent TEVAR. Indications for
treatment were malperfusion - 26 (60%) and rupture - 22 (51%); 5 (11%)
presented with both. Renal malperfusion was present in 17 (65%), visceral -
17 (65%), lower extremity - 14 (54%). Patients were followed 1 to 49
months (16  12).
Results: Excellent technical and clinical results were achieved in both
groups. Onset of intervention was significantly earlier in patients with
rupture (0.6 vs. 1.9 days, p0.02). Endograft utilization and deployment
were comparable, including device number (2.1; 2.2; p0.94), left SCA
coverage (17; 16; p0.58), and celiac coverage (0; 0). One-year survival was
greater than 94% in both groups. While length of stay was longer with
malperfusion, neither presentation conferred an inferior outcome (Table).
Although TEVAR alone effectively treated aortic rupture in 21 patients
(95%), malperfusion was rectified in only 15 (58%) cases. Eleven patients
(42%) required adjunctive procedures to restore end-organ perfusion: 50%
-lower extremity, 18% - renal, 12% - visceral. No patient suffered limb loss or
bowel resection; renal function recovered in 94% of patients with malperfu-
sion.
Conclusions: Malperfusion and rupture complicating acute type B
aortic dissection are both successfully managed with TEVAR. However, the
endovascular strategy must be customized to each presentation to achieve
these results. While TEVAR alone is sufficient to address the aortic disrup-
tion in patients with rupture, adjunctive procedures are often necessary in
malperfusion cases.
Malperfusion Rupture P value
ICU stay (days) 5.1  0.8 6.4  0.8 0.98
LOS (days) 19.6  2.5 13.2  1.2 0.04
Blood products
(patients)
15/26 9/22 0.59
Stroke (patients) 0/26 1/22 0.93
Spinal ischemia
(patients)
2/26 1/22 0.65
30-day mortality
(patients)
0/26 1/22 0.93
1-year survival
(patients)
21/22 16/17 0.85
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Fairman, None; B.M. Jackson, None; G.W. Moser, None; E.Y. Woo,
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SS10.
Temporary IVC Filters Usually Become Permanent Except When
Placed in Trauma Patients for Prophylactic Indications
Peter B Brant-Zawadzki, Faheem Akhtar, Michelle T Mueller, Daniel V
Kinikini, Larry W Kraiss, Mark R Sarfati. University of Utah, Salt Lake City,
UTObjective(s): The optimal use of retrievable IVC filters remains un-
clear. We compared our recent 5-year experience with retrievable filters
placed for prophylactic or therapeutic indications.
Methods: A retrospective, single institution chart review was per-
formed to identify patients who had a retrievable filter placed between July
2002 and December 2007. Patient data included age, sex, admitting diag-
nosis, indication for filter, dates of insertion, retrieval/attempted retrieval
and reasons for unsuccessful retrieval. Comparisons were made by Chi-
square testing.
Results: During the study period, 462 retrievable filters were placed
in patients who had a confirmed diagnosis of VTE (or were considered
high risk for VTE) who also had an absolute or relative contraindication
to anticoagulation. Overall, a retrieval attempt was made in 201 (44%)
patients and was successful in 174 (87% of attempts but only 38% of all
filters placed) [See table]. Retrieval was much more likely to be attempted
in patients who received filters for prophylactic (64%) v therapeutic (28%)
indications (p 0.0001). Lack of an attempt to retrieve the filter was due
to loss of follow-up (n  141; no difference between prophylactic or
therapeutic groups), contraindication to anticoagulation (n  75), or
patient death (n  46). Retrieval failure (n  27) was due to: filter
ingrowth (n 11), retained thrombus (n 10), or tilt (n 6). Duration
of implantation 30 days was strongly and inversely correlated with
retrieval success [30 day retrieval rate  92% (131/142), 30 day
retrieval rate  73% (43/59); p  0.0002].
Conclusions: The only group with a 50% retrieval rate were trauma
patients who received prophylactic filters. All other patient groups were
more likely to have their filters left in permanently. If attempted, retrieval
rates were relatively high regardless of indication or underlying diagnosis
although duration of implantation was a significant factor in unsuccessful
filter retrieval.
Comparison between Prophylactic & Therapeutic Filters
Prophylactic
(no confirmed VTE)
Therapeutic
(confirmed VTE)
N [Total  462] (%) 194 (42) 268 (58)
Attempted Retrieval (%) 125 (64) 76 (28)
Successful Retrieval
(% of attempts)
111 (89) 63 (84)
Retrieval Rate (%) by
Diagnosis
Trauma (n  114/188,
61%)
98/150 (65) 16/38 (42)
Cancer (n  10/85, 12%) 1/10 (10) 9/75 (12)
Neuro (n  6/34, 18%) 3/8 (38) 3/26 (12)
Ortho (n  11/32, 34%) 4/13 (31) 7/19 (37)
Other Med/Surg
(n  33/123, 27%)
5/13 (38) 28/110 (25)
Author Disclosures: P.B. Brant-Zawadzki, None; F. Akhtar, None;
M.T. Mueller, None; D.V. Kinikini, None; L.W. Kraiss, None; M.R.
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SS11.
Aggressive Lipid-Lowering is More Effective Than Moderate Lipid-
Lowering Treatment in Carotid Plaque Stabilization
Nikolaos P EKadoglou1, Nikolaos Sailer1, AnestisMoumtzouoglou1, Alkis-
tis Kapelouzou2, Grigorios Fotiadis1, Ioulia Vitta1, Ioannis Kakisis3, Ef-
thimios Avgerinos3, Thomas Gerasimidis1, Panayotis Karayannacos2, Chris-
tos D Liapis1. 1Aristotle’s University of Thessaloniki, Thessaloniki, Greece;
2Foundation of Biomedical Research, Academy of Athens, Athens, Greece;
3University of Athens, Athens, Greece
Objective: Atherosclerotic plaque stabilization is a promising strategy
to prevent cerebrovascular events in patients with moderate carotid stenosis.
This prospective study examined whether intensive lipid-lowering therapy is
more effective in increasing carotid plaque echogenicity, assessed by Gray-
Scale Median (GSM) score, and suppressing serum levels of osteopontin
(OPN) and osteoprotegerin (OPG) in patients with carotid stenosis.
Methods: 120 patients (51M/69F), aged 55-75, with carotid stenosis
(NASCET: 40-60% for symptomatic and 40-70% for asymptomatic pa-
tients), thus without indications for surgical intervention, were included.
Patients with previous use of statins were excluded. Patients were random-
ized to either intensive lipid-lowering therapy (Group A; n60: target
LDL-C70mg/dl) or moderate lipid-lowering therapy (Group B; n60:
target LDL-C100mg/dl). The ratio symptomatic/asymptomatic patients
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80mg gradual titration) to reach the target. Biochemical parameters and
GSM score were assessed at baseline and after 12 months. Independent
samples t-test and Pearson correlation were used for statistical analysis
(p0.05).
Results: There were no significant differences between groups at
baseline. Group A showed a more pronounced improvement in lipid profile
compared with group B (p0.05). Moreover atorvastatin treatment signif-
icantly suppressed of hsCRP, OPN and OPG serum levels across LDL levels
downregulation (p0.05). ). Remarkable increment of carotid plaque echo-
genicity was noted in both groups, but that was considerably higher in group
A than group B (table 1).Notably GSM score augmentation was inversely
associated with OPN (p0.031) and OPG (p0.002) changes in the whole
study group.
Conclusions: Intensive lipid-lowering therapy rather than moderate
lipid-lowering therapy is more effective in increasing echogenicity of carotid
plaques. This effect seems to be mediated by OPN and OPG suppression.
Table 1. Changes of lipid parameters, osteopontin,
osteoprotegerin, hsCRP and GSM in both groups
Group A Group B
pBaseline Change Baseline Change
T.Cholesterol
(mg/dl)
200.644.1 68.517.2* 20950.6 45.114.3* 0.048
HDL-C (mg/
dl)
36.610 4.61.1* 34.213.6 1.30.5 0.017
LDL-C (mg/dl) 153.836.5 7422.9* 146.143.3 44.910.8* 0.018
Triglycerides
(mg/dl)
151.350.2 3714.4* 168.772.4 36.79.2* 0.984
Osteopontin
(ng/ml)
74.6328.64 45.924.6* 71.8931.58 22.411.5* 0.002
Osteoprotegerin
(pmol/L)
7.041.58 3.82.3* 7.562.37 2.841.3* 0.038
hsCRP (mg/L) 5.372.35 2.881.1* 5.53 2.10.55* 0.067
GSM 63.717.6 28.035.92* 63.112.6 20.814.33* 0.030
p values of changes of variables between groups (A vs B).
*p0.05 values of changes of variables within groups.
Author Disclosures: N.P.E. Kadoglou, Project Pythagoras II; Common
Research Project “Hellas-Slovenia”; Grant by the Onassis Public Benefit
Foundation; N. Sailer, None; A. Moumtzouoglou, None; A. Kape-
louzou, None; G. Fotiadis, None; I. Vitta, None; I. Kakisis, None; E.
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Unexpected Major Role for Venous Stenting in Reflux Disease: Symp-
tom Relief With Partial Correction of Pathology
Seshadri Raju1,2, Rikki Darcey2, Peter Neglen2. 1University of Mississippi
Medical Center, Jackson, MS; 2River Oaks Hospital, Flowood, MS
Background: Pathology of Postthrombotic venous disease (PTS) has
been known to be a combination of obstruction and reflux. Recent use of
IVUS has found that obstructive non-thrombotic iliac vein lesions (NIVL)
are found in over 90% of symptomatic ‘primary’ cases with reflux as well.
Correction of the obstructive component alone in both types of chronic
venous insufficiency (CVI) yielded unexpected substantial symptom relief
minimizing the need for correction of associated reflux with complex open
surgery.
Patients and Methods: From 1997 to 2008 (11yrs) iliac vein stent
procedures were performed in 1487 limbs to relieve obstruction. 513 had
associated deep reflux (with superficial reflux in 366, 71%). Superficial reflux
alone was present in 345 and excluded. Clinical (CEAP) classification was
C2 (pain) in 4%; C3 in 44%; C4 in 21%; C5 in 6%; and C6 in 25%. Etiology
was ‘primary’ in 213 (42%) and postthrombotic in 300 (58%) limbs. Reflux
segment score was 3, (0-8) (median, range). Severe reflux (reflux segment
score3 and/or axial reflux) was present in 296 (58%) which also included
271 limbs with ‘axial reflux.’ Median (range) percentage drop & VFT
(ambulatory venous pressure) were 62 % (10-90) mm Hg & 16 sec. (1-23)
respectively; median VFI 90 (APG) was 2.8 sec (0.5-16.6).
Results: Cumulative secondary stent patency (6 Yrs) was 100 % and 87
% respectively for NIVL and PTS limbs. Complete relief of pain occurred in
83 % and significant improvement ( 3 VAS) in 89% post-stent. Complete
relief of swelling occurred in 46% and significant improvement ( 1 grade)
in 71% post-stent. Complete healing/freedom from recurrence (C 4,5,6)
was 63% at 5 years. QOL (CIVIQ) improved significantly. Clinical outcomes
were similar (p NS) between NIVL and PTS limbs and between severe orlesser reflux subsets. Reflux parameters did not get worse post stent: per-
centage drop- 63% mmHg (10-90) and VFT 16 sec. (1-23) were un-
changed; VFI90 2.1 sec. (0.5-13.2) was improved (p0.002).
Conclusions: Combined obstruction/reflux is often present in CVI of
post-thrombotic or primary aetiologies. Substantial symptom relief is ob-
tained by percutaneous stenting alone ie. CVI responds to partial correction
of combined pathology with stent and the residual reflux is well tolerated.
These findings provide the basis for a new paradigm in the treatment of CVI.
Author Disclosures: S. Raju, None; R. Darcey, None; P. Neglen, None.
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High Brachial Artery Bifurcation Is Associated With Failure Of Upper
Limb Autologous Arteriovenous Fistulae
Domenico Valenti, HirenMistry, Cornelia Junghans, NiamhHaughey, Ben
Freedman, Mark Tyrrell. King’s College Hospital, London, United King-
dom
Objective: Although European Best Practice Guidelines on vascular
access recommend universal pre-operative duplex scan in patients receiving
brachio-cephalic (BC) arteriovenous fistulae (AVF), this is not widespread
practice. Furthermore, cadaveric and angiographic studies suggest that
variation in upper limb arterial anatomy is common. Our aim was to
investigate the prevalence of high brachial artery bifurcation and its impact
on BC AVF patency.
Methods: A prospective analysis of consecutive autologous BC AVF
procedures over an 18 month period (January 2007-June 2008). Patients
with high bifurcations identified at duplex scan were compared with a
randomly selected age and sex matched population of those with normal
bifurcations. Patients were followed up at 1, 6 and 12weeks post operatively.
The study endpoint was AVF failure.
Results: 258 procedures were performed on 239 patients (male: female
ratio 150:89, median age 64, range 29-88). 29 (12%, of whom 57% were
male) had high brachial bifurcations. The bifurcation was axillary in 6
patients and at the proximal, middle and distal third humerus level in 9, 7
and 7 patients respectively. At 12 months, the actuarial risk of AVF failure
was greater in those with high than those with normal bifurcations (45%
(95% CI 26-69%) vs. 23% (95% CI 14-37%). Neither gender nor cause of
renal failure predicted either aberrant upper limb arterial anatomy or AVF
failure.
Conclusions: These data show that aberrant brachial artery anatomy is
both common (12%) and a powerful independent predictor of AVF failure.
These data support the universal use of pre-AVF duplex scanning.
Author Disclosures: D. Valenti, None; H. Mistry, None; C. Junghans,
None; N. Haughey, None; B. Freedman, None; M. Tyrrell, None.
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Brachial Vein Transposition Arteriovenous Fistulas for Hemodialysis
Access
William C Jennings, Matthew J Sideman, Kevin E Taubman, Thomas A
Broughan. University of Oklahoma College of Medicine, Tulsa, Tulsa, OK
Background: The National Kidney Foundation Dialysis Outcomes
Quality Initiative and the National Vascular Access Improvement Initiative
“Fistula First” recommend arteriovenous fistulas (AVF) as the preferred
vascular access for hemodialysis. AVFs have lower morbidity and mortality
rates in addition to lower yearly Medicare cost profiles, as opposed to grafts
or catheters. Complex medical illnesses and previous failed access operations
leave some individuals with a difficult access extremity, confronting surgeons
with obliterated cephalic and basilic veins. Brachial vein transposition AVFs
(BVT-AVF) have been reported with mixed results in these patients. We
review our experience and techniques with BVT-AVFs.
Methods: We analyzed the records of consecutive patients in our
vascular access database who had BVT-AVFs constructed from September
2006 to December 2008. Most BVT-AVFs were created in staged proce-
dures. The second stage transposition operations were generally completed
4 to 6 weeks after the first stage AVF operation. A single stage BVT-AVFwas
utilized when the brachial vein diameter was  6 mm. All patients were
evaluated with pre and post-operative ultrasound examinations by the
operating surgeon.
Results: 52 BVT-AVF procedures were identified. Of these, 35(67.3%)
were women, 25(48.1%) were diabetic, and 26 (50.0%) had previous access
surgery. 46 operations were completed in two stages and 6 as a single
procedure. Follow-up was 1-25 months (mean  6 mos). Primary patency,
primary assisted patency, and cumulative (secondary) patency were 33.5%,
79.8%, and 91.7% at 12 months and 25.1%, 79.8%, and 91.7% at 24 months,
respectively. No prosthetic grafts were used in any patient.
